Approximately 20% of breast cancers overexpress human epidermal growth factor receptor 2 (HER2+), conferring a particularly aggressive subtype of the disease with an increased risk for the development of systemic and brain metastases. However, the advent of trastuzumab and more recently several other ...
MARGENZA is a prescription medicine approved for use in combination with chemotherapy for the treatment of adult patients with metastatic HER2+ breast cancer.
The therapeutic landscape for HER2-positive metastatic breast cancer has exploded in the last two decades following the initial advent of trastuzumab, a monoclonal antibody. While the first line treatment has remained a combination of dual HER2 blockade with taxane chemotherapy, we now have several ex...
Closing out his discussion on HR+/HER2- metastatic breast cancer, Kevin Kalinsky, MD, MS, highlights key takeaways and shares excitement for future evolutions in the treatment paradigm. This is a modal window. The Playback API request failed for an unknown reason Error Code: VIDEO_CL...
Dr Sardesai on Lasofoxifene Plus Abemaciclib in ESR1-Mutant, ER+/HER2– Breast Cancer Effects of trastuzumab deruxtecan (T-DXd) on health-related quality of life (HRQOL): DESTINY-Breast12 (DB-12) results Dr Grinshpun on Ultra-Sensitive ctDNA Detection in HR+ Early Breast Cancer ...
Komal Jhaveri, MD, FACP, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses sequencing treatments for patients with metastatic HER2-positive breast cancer. When a patient begins frontline treatment, Jhaveri recommends the use of trastuzumab (Herceptin), pertuzumab (Perjeta), and ...
Human epidermal growth factor receptor 2 (HER2) overexpression drives the biology of 20% of breast cancers, and predicts a poor prognosis for patients. HER2-targeted therapies significantly improve outcomes for HER2-positive patients with both early and metastatic breast cancer. Currently three HER2-ta...
In an interview with Pharmacy Times, Kelly Gaertner, PharmD, an oncology clinical pharmacy specialist with Allegheny Health Network, said that a slew of new treatments for human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer offer exciti...
breast cancer cells would become sensitive to estrogen deprivation again. In laboratory cell lines, they treated the cancer cells with neratinib, an irreversible inhibitor of HER2, and fulvestrant, and found that this combination overcame the drug resistance that had developed in the metastatic cancer...
Cancer Medicine ORIGINAL RESEARCH Open Access Physician experiences and preferences in the treatment of HR+/HER2− metastatic breast cancer in the United States: a physician survey Peggy L. Lin1, Yanni Hao2, Jipan Xie3, Nanxin Li1, Yichen Zhong1, Zhou Zhou1, James...